Alimera Sciences to Report Second Quarter 2017 Financial Results on August 2nd, 2017

ATLANTA, July 24, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences ALIM, a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the second quarter ended June 30, 2017, after the close of the financial markets on Wednesday, August 2, 2017.

An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. The call will be held at 9:00 AM ET, on Thursday, August 3, 2017. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Details

Conference date: Thursday, August 3, 2017 9:00AM ET

Conference dial-in: 877-269-7756

International dial-in: 201-689-7817

Conference Call Name: Alimera Sciences' Second Quarter 2017 Results Call

Webcast Registration: Click Here

Following the live call, a replay will be available on the Company's website, www.alimerasciences.com, under "Investor Relations".

About Alimera Sciences

Alimera Sciences, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in its product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.

Contact
CG CAPITAL
Rich Cockrell
877.889.1972
investorrelations@cg.capital

Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsHealth CarePress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!